Jacobs Levy Equity Management
CTIC

Jacobs Levy Equity Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Jacobs Levy Equity Management’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-184,724
Closed -$920K – 1139
2018
Q2 		$920K Buy
184,724
+147,904
+402% +$647K 0.01% 683
2018
Q1 		$144K Sell
36,820
-50,028
-58% -$176K ﹤0.01% 958
2017
Q4 		$233K Buy
86,848
+16,328
+23% +$47.9K ﹤0.01% 875
2017
Q3 		$225K Buy
70,520
+26,800
+61% +$89.5K ﹤0.01% 838
2017
Q2 		$145K Buy
43,720
+11,483
+36% +$44.7K ﹤0.01% 875
2017
Q1 		$135K Sell
32,237
-2
-0% -$9 ﹤0.01% 836
2016
Q4 		$131K Sell
32,239
-59,681
-65% -$248K ﹤0.01% 872
2016
Q3 		$344K Sell
91,920
-24,970
-21% -$90.9K 0.01% 781
2016
Q2 		$397K Buy
+116,890
New +$536K 0.01% 817
2015
Q4 		– Sell
-4,680
Closed -$68K – 942
2015
Q3 		$68K Sell
4,680
-10,210
-69% -$176K ﹤0.01% 782
2015
Q2 		$290K Buy
14,890
+2,070
+16% +$40K 0.01% 665
2015
Q1 		$232K Buy
12,820
+1,670
+15% +$37.6K ﹤0.01% 679
2014
Q4 		$263K Buy
+11,150
New +$258K ﹤0.01% 708
2014
Q2 		– Sell
-1,340
Closed -$46K – 1038
2014
Q1 		$46K Hold
1,340
– – ﹤0.01% 873
2013
Q4 		$26K Sell
1,340
-25,558
-95% -$465K ﹤0.01% 932
2013
Q3 		$436K Sell
26,898
-67,469
-71% -$782K 0.01% 726
2013
Q2 		$991K Buy
+94,367
New +$1.11M 0.02% 576

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Jacobs Levy Equity Management's CTIC Position: Q3 2018 in Review

Jacobs Levy Equity Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q3 2018, closing a stake of 184,724 shares — an estimated $920K sold.

Jacobs Levy Equity Management first reported a position in CTIC in Q2 2013 and held it in 17 quarters. The position peaked at $991K in Q2 2013. 79 funds tracked by Wall St. Rank hold CTIC as of Q3 2018.

  • Jacobs Levy Equity Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q3 2018 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 184,724 CTI BioPharma Corp. (DE) Common Stock shares in Q3 2018, an estimated $920K.
  • Jacobs Levy Equity Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2013 and held it in 17 quarters.
  • Jacobs Levy Equity Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $991K in Q2 2013.
  • 79 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q3 2018.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2018, filed 14 Nov 2018.